Delhi AIIMS, University of Liverpool collaborate for research in head, neck cancer

The Union Health Minister also presided over the signing of a Collaboration Agreement between University of Liverpool and AIIMS New Delhi for “AIIMS Liverpool Collaborative Centre for Translational Research in Head and Neck Cancer – ALHNS”. The ALHNS will build upon the pre-existing collaboration and links between the Liverpool Head and Neck Centre (LNHC), University of Liverpool and the Head and Neck Cancer Unit at AIIMS New Delhi.

Written By :  Kajal Rajput
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-02-13 10:30 GMT   |   Update On 2024-03-27 09:27 GMT

Jhajjar: Dr Mansukh Mandaviya, Union Minister for Health and Family Welfare yesterday virtually addressed the 5th Foundation Day celebration of National Cancer Institute (NCI) of AIIMS Jhajjar. Ms Christina Scott, British Deputy High Commissioner to India was also present on the occasion. 

Addressing the gathering, Dr Mandaviya said, “The way NCI has progressed over the last 5 years, is a testament to the skill and dedication of the doctors, nurses and other health workers involved in the day to day functioning of the institute.” He encouraged the institute to continue delivering quality healthcare to patients.

Also Read:PM Modi inaugurates Vishram Sadan at NCI in AIIMS Jhajjar campus

The Union Health Minister also presided over the signing of a Collaboration Agreement between University of Liverpool and AIIMS New Delhi for “AIIMS Liverpool Collaborative Centre for Translational Research in Head and Neck Cancer – ALHNS”. The ALHNS will build upon the pre-existing collaboration and links between the Liverpool Head and Neck Centre (LNHC), University of Liverpool and the Head and Neck Cancer Unit at AIIMS New Delhi.

ALHNS will impact the care of patients with head and neck cancer by combining resources at both institutions in order to develop joint research and education programmes which will enhance the quality of research outputs and education.

It also aims to develop common SOPs so as to access high quality clinical datasets and tissue repositories of two ethnically diverse populations whose cancer-causing aetiologies differ significantly (cigarette smoking, alcohol drinking and Human papillomavirus in the UK population, in contrast to smokeless tobacco products in an Indian population). ALHNS also aims to have commonly articulated strategic goals in order to deliver cutting edge medical innovation and personalized cancer treatments.

Dr Mandaviya stated that “Hon’ble Prime Minister's dream is that the country should become Ayushman, where health facilities become affordable, accessible and available to every citizen. There should be no discrimination between rich and poor for treatment. To ensure that everyone gets healthcare facilities with the same quality standard, the government has worked in the last 10 years by linking the health sector with development.” On the achievements of the Ayushman Bharat PM-JAY and Ayushman Arogya Mandir scheme, he said, “By providing family health insurance of Rs 5 lakh annually to 60 crore people of the country, free treatment for serious diseases has been provided. Under this scheme, today even the poor get their treatment in those hospitals where earlier only rich people used to get their treatment.

Till now, more than 6 crore people have received treatment under this scheme, due to which these poor people have saved more than Rs 1,12,500 crore.” “One of the purposes behind establishing over 1.64 lakh Ayushman Arogya Mandirs is to ensure that primary cancer screening is done in the first stage itself. Today, complex operations are being conducted in district hospitals as well”, he added. He further said that Ayushman Bharat Yojana has not only saved the lives of crores of people but has also kept them from falling below the poverty line.

On India’s successes in the endeavor to eliminate TB by 2025, Dr Mandaviya said, “Under the Prime Minister's TB Free India Campaign, every year 25 lakh TB patients of the country are provided free medicines, testing, nutrition etc., in which approximately Rs 3000 crore is spent annually. Apart from this, financial assistance of Rs 500 per month is also given to TB patients, in which Rs 2756 crore has been paid directly into the accounts of the patients in the last 5 years. He also highlighted that 10 lakh TB patients of the country are being adopted by service-minded citizens and are also distributing nutrition to them every month.

The Union Health Minister also mentioned the Sickle Cell Elimination Program of the Indian Government in which sickle cell screening of about 7 crore people will be done in 3 years and medicines for sickle cell will be made available for free, on which the government will spend about Rs 910 crore.

The National Cancer Institute, Jhajjar was dedicated to the nation on 12th February 2019 by Hon’ble Prime Minister Shri Narendra Modi. NCI Jhajjar registers average daily OPD patient footfall of over 500 and registers over 60 cancer patients every OPD day. It also registers weekly average of 800-1000 sessions of radiation therapy, while chemotherapy day care admissions had surpassed 30,000 in 2023. NCI Jhajjar boasts of state-of-the-art modular operation theatres where an average of 80-100 onco surgeries are conducted weekly.

NCI Jhajjar recently started new oncology and yoga facilities, focusing on both cure and care of patients. It also provides spiritual cancer care, physiotherapy, psycho-oncology and oncology survivorship services to its patients, focusing on holistic cancer care.

Prof. Dr M Srinivas, Director, AIIMS New Delhi; Prof Tim Jones, Vice Chancellor, University of Liverpool; Prof. Alok Thakar, Head, NCI-AIIMS, senior officials of the Union Health Ministry and faculty members of AIIMS New Delhi were also present.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News